Chief, Myeloma Service
Dr. Landgren is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. He has a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma and is one of the pioneers in the development of MRD testing in myeloma. In collaboration with colleagues at MSK as well nationally/internationally, he develops new strategies (including cell-based, molecular-based, and imaging-based) and implements advanced MRD testing in clinical trials at MSK.
years treating myeloma: 17
Number of Myeloma Patients Treated Annually: 100-200
Details & contact info
York Avenue Manhattan
New York City, NY, United States, 10128
Send a message to Ola C. Landgren, MD, PHD